SCHEDULE 13G: RTW Investments Discloses 6% Stake in Apogee Therapeutics
Beneficial Ownership Disclosure
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 6% beneficial ownership stake in Apogee Therapeutics, Inc. as of December 31, 2024.
Summary
- RTW Investments, LP, a Delaware limited partnership, and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer, have filed a Schedule 13G.
- The filing indicates beneficial ownership of 2,712,097 shares of Common Stock of Apogee Therapeutics, Inc.
- This ownership represents 6.0% of the outstanding Voting Shares of Apogee Therapeutics, Inc.
- The percentage is calculated based on 45,026,556 Voting Shares outstanding as of November 5, 2024, as reported in the Company's Form 10-Q.
- Both RTW Investments, LP and Roderick Wong, M.D. share voting and dispositive power over all 2,712,097 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure by an institutional investor, RTW Investments, LP, indicating a significant passive ownership stake in Apogee Therapeutics, Inc. Such filings are common in the investment industry, providing transparency on large shareholdings and often signaling an investor's confidence in a company's long-term prospects, without necessarily implying an intent to influence management or control.
Related Party Transactions
- Roderick Wong, M.D. is the Managing Partner and Chief Investment Officer of RTW Investments, LP, and is filing jointly with RTW Investments, LP regarding the shares held by the RTW Funds.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed as a vote of confidence or a potential source of future liquidity.
- Management: Awareness of a large, passive shareholder, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 11/05/2024 | Date as of which 45,026,556 Voting Shares of Apogee Therapeutics, Inc. were reported outstanding in the Company's Form 10-Q. |
| 11/12/2024 | Date Apogee Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 12/31/2024 | Date of event which requires the filing of this Schedule 13G statement. |
| 02/14/2025 | Date the Schedule 13G statement was signed by RTW Investments, LP and Roderick Wong, M.D. |
Keywords
Apogee Therapeutics, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.